Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.

• Status: Active, not recruiting
• Trial end date: 2025-08-01
• Target enrollment: 0
• Participant gender: Female

Summary

The aim of this prospective, randomized, multicenter, open-label, phase II study is to test if chemotherapy can be replaced by the combination of ribociclib plus letrozole as a neo-adjuvant therapy for patients with non-metastatic primary luminal breast cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Borstkanker Onderzoek Groep
• Collaborators: Novartis; Philips Healthcare
• Treatments: Hormones; Letrozole; Phenobarbital

Criteria

Inclusion Criteria:

• Postmenopausal women presenting with histological proven (core biopsy material) hormone receptor positive (ER≥50%, PR any), HER2 negative, stage II/ III breast cancer.

• Measurable disease (breast and/or lymph nodes)

• WHO 0-2

• Adequate bone marrow function (within 4 weeks prior to registration): WBC≥3.0x109/l, neutrophils ≥1.5 x 109/l, platelets ≥100 x 109/l

• Adequate liver function (within 4 weeks prior to registration): bilirubin ≤1.5 x upper limit of normal (UNL) range, ALAT and/or ASAT ≤2.5 x UNL, Alkaline Phosphatase ≤5 x UNL

• Adequate renal function (within 4 weeks prior to registration): the calculated creatinine clearance should be ≥50 ml/min

• Accessible for treatment and follow-up

• Written informed consent

Inclusion criteria randomization specific:

In order to be eligible to be randomized in this study, a subject must meet all of the following criteria:

• Registration in the NEOLBC trial before 2 weeks biopsy

• Use of letrozole

• Outcome central Ki67 determination in two weeks biopsy available.

Exclusion Criteria:

• Evidence of distant metastases (M1)

• Previous invasive breast cancer

• Prior chemotherapy, radiation therapy or hormonal therapy with the exception of patients who received letrozole ≤ 14 days (+ max. 4 days) prior to registration and who are still on letrozole.

• Previous malignancy within 5 years, with exception of a history of a previous basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix.

• Peripheral neuropathy > grade 2, whatever the cause

• Serious other diseases as infections (hepatitis B, C and HIV), recent myocardial infarction, clinical signs of cardiac failure or clinically significant arrhythmias or on screening, any of the following cardiac parameters: bradycardia (heart rate <50 at rest) or QTcF ≥450 msec.

• Known hypersensitivity reaction to any of the components of the treatment (peanuts, soy)

• Currently receiving warfarin or other coumarin derived anti-coagulant, for treatment, prophylaxis or otherwise. Therapy with heparin, low molecular weight heparin (LMWH), or fondaparinux is allowed.

• Currently receiving any of the following substances and cannot be discontinued 7 days prior to randomisation:

• Known strong inducers or inhibitors of CYP3A4/5, including grapefruit, grapefruit hybrids, pummelo's, star-fruit, pomegranate and Seville oranges.

• That have a known risk to prolong the QT interval or induce Torsades de Pointes.

• That have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5.

• Herbal preparations/medications, dietary supplements.

• Medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or sign meaningful informed consent.